TIDM57MC
RNS Number : 0101Z
Wellcome Trust Finance plc
12 December 2017
Wellcome Trust Finance plc
Annual Report and Financial Statements
Wellcome Trust and Wellcome Trust Finance plc. (a wholly owned
subsidiary of Wellcome Trust) announce that they have each
published their Annual Report and Financial Statements for the year
to 30 September 2017 today. A copy of each document is available on
the Wellcome Trust website.
Wellcome Trust has today issued the following press release in
connection with the publication of its Annual Report and Financial
Statements:
The Wellcome Trust is pleased to report that our investment
portfolio recorded a total return of 16.9% per cent for the year to
30 September 2017, equating to GBP3.5 billion on an investment
portfolio value of GBP20.9 billion at the start of the year. Our
charitable expenditure increased by 14% to GBP1.1 billion and the
investment base rose to GBP23.2 billion.
Returns have been 138 per cent cumulative (9.1 per cent
annualised) over ten years, a period which included the worst
economic crisis in a generation, and 407 per cent cumulative (8.5
per cent annualised) over 20 years. Since the inception of our
investment portfolio in 1985, it has provided a total return
averaging 13.9 per cent a year. We maintain a AAA/aaa (stable)
credit rating.
This year, we again enjoyed double-digit returns from every
asset class except property. Each major element of the portfolio
(public equities, private equities, venture capital, hedge funds
and property) has performed strongly over the longer term. Currency
movements were less influential this year, with Sterling
strengthening slightly so that the US Dollar return was 20.7 per
cent.
Danny Truell announced earlier in the year that for health
reasons he was moving to an advisory role. After a global search
conducted by David Barrett Partners, Wellcome decided to retain
Nick Moakes and Peter Pereira Gray as the Managing Partners of the
Investment Division, and additionally appoint Nick as Chief
Investment Officer, and Peter as Chief Executive Officer of the
Investment Division.
Baroness Manningham-Buller, Chair of the Trust, said: "I am
pleased to report that, once again, our investments have done well.
The performance of the endowment has enabled us to commit to
maintaining charitable expenditure in real terms at record levels.
The level of spending is now double that of a decade ago, which
puts Wellcome in the top tier of global funding organisations. Our
sincere thanks go to Danny Truell for his remarkable and invaluable
contribution over the past twelve years. We are confident that
having achieved a smooth succession, Wellcome's financial future
will continue to be bright."
Wellcome Trust Finance plc. further announces that a copy of its
Annual Report and Financial Statements for the year ended 30
September 2017 has been submitted to the National Storage
Mechanism, and will shortly be available for inspection at
http://www.morningstar.co.uk/uk/NSM.
In accordance with the Disclosure and Transparency Rules, the
following information is taken from the Annual Report and Financial
Statements for Wellcome Trust Finance plc. for the year ended 30
September 2017.
Wellcome Trust Finance plc
Annual Report and Financial Statements
Year ended 30 September 2017
Strategic Report
The Directors of Wellcome Trust Finance plc present their
Strategic Report for the year ended 30 September 2017.
Strategy and Objectives
The principal activity of Wellcome Trust Finance plc (the
"Company") is to meet its obligations relating to the bonds that it
has previously issued on the London Stock Exchange and to continue
to lend the proceeds to other group entities.
Review of the Business and Future Developments
The Company issued two tranches of bonds: GBP550 million on 25
July 2006 of 4.625% Guaranteed Bonds due July 2036 and GBP275
million on 28 May 2009 of 4.750% Guaranteed Bonds due May 2021 (the
"Bonds"). The Bonds are listed on the London Stock Exchange. The
obligations of the Company in relation to the Bonds are governed by
Trust Deeds between the Company, The Wellcome Trust Limited, as
trustee of the Wellcome Trust, and Citicorp Trustee Company
Limited, as the trustee for the holders of the Bonds. The payment
of all amounts due in respect of the Bonds is unconditionally and
irrevocably guaranteed pursuant to the terms of a guarantee given
by The Wellcome Trust Limited, as corporate trustee of the Wellcome
Trust; the guarantee is part of the Trust Deeds.
The Company loaned the proceeds from the Bonds issued to
Wellcome Trust Group (the "Group") undertakings and receives
interest on these loans.
The Company will continue to receive interest on the loans to
Group undertakings and pay interest on the Bond liabilities for the
foreseeable future.
Results for the Year
The Company made a profit of GBP3,445,332 (2016: GBP3,463,413)
during the year ended 30 September 2017. As at 30 September 2017
the Company had net assets of GBP137,500,000 (2016:
GBP137,500,000).
Key Performance Indicators
Due to the nature of the Company's operations, the key
performance measures are that the Company meets all its legal
obligations to the Bond holders and that the Company achieves
sufficient return on its assets to be profitable, before any
donations to the Wellcome Trust under Gift Aid. During the year the
Company met all its legal obligations to the Bond holders and made
a net profit before donations to Wellcome Trust under Gift Aid.
Financial risk management objectives and policies
The Directors of the Company implement policies to manage the
inherent risks relating to the financial assets and liabilities of
the Company.
The Directors have assessed for each financial asset and
liability: the market risk, currency risk, interest rate risk,
liquidity risk, and credit risk exposure. The Company is not
exposed to significant market risk or interest rate risk because
the Company's main financial assets have fixed redemption values,
fixed interest rates and fixed maturity dates, which match those of
its financial liabilities. The currency risk exposure is limited to
the payment of one administrative expense amount per annum. The
liquidity risk of the Company is mitigated by the matching of the
cash flows from the Company's financial assets and liabilities.
Credit risk exposure of the Company's loans is reduced by the
Company only advancing loans to entities within the Group. Credit
risk exposure of the Company's remaining financial assets is
reduced by stringent selection procedures for any external
counterparties with which the Company transacts.
Due to the fixed nature of the Company's assets and liabilities,
there is very little risk to which the Company is exposed.
The Company's internal control and risk management is undertaken
as part of the Wellcome Trust's processes. The key elements of this
specifically applicable to the Company are:
-- delegation: there is a clear organisational structure with
documented lines of authority and responsibility for control and
documented procedures for reporting decisions, actions and issues;
and
-- review: the Group Audit Committee reviews the effectiveness
of the Company's internal control, its financial reporting process,
the independence of its statutory auditors and its compliance with
relevant statutory and finance regulations and advises the
Directors of the Company of any relevant matters.
Corporate and Social Responsibility
Due to the nature of its activities the Company has a minimal
environmental impact. Social responsibility of the Group is
detailed in the Wellcome Trust Annual Report and Financial
Statements, which are available at www.wellcome.ac.uk.
This report was approved by the Board of Directors and signed on
its behalf on 11 December 2017 by:
Peter Pereira Gray
Director
11 December 2017
Directors' Report
Report of the Directors
The Directors of Wellcome Trust Finance plc present their report
and the audited Financial Statements for the year ended 30
September 2017.
Future developments
These are discussed in the Strategic Report.
Financial risk management objectives and policies
These are discussed in the Strategic Report.
Employees
There are no employees of the Company (2016: nil).
The management and administration of the Company is undertaken
by staff from the Group. The Group has not incurred any incremental
staff costs due to the management of this Company.
Dividend
The Directors do not propose the payment of a dividend (2016:
GBPnil).
Corporate Governance
The Company is limited by shares. Its governing documents are
its articles of association. The shareholder of the company is The
Wellcome Trust Limited, as trustee of the Wellcome Trust.
The Company is considered to be a wholly owned subsidiary of the
Wellcome Trust through its corporate trustee, The Wellcome Trust
Limited. The Company is not subject to the requirements of the UK
Corporate Governance Code. The governance policies of the Group and
of the Wellcome Trust is included in the Wellcome Trust's Annual
Report and Financial Statements for the year ended 30 September
2017.
The Audit Committee, the Investment Committee and the internal
audit function of the Wellcome Trust oversee all group
entities.
The Company complies with all appropriate filing and information
requirements of the Financial Conduct Authority.
Directors and their interests
The Directors of the Company who were in office during the year
and up to the date of signing the Financial Statements were:
Nicholas Moakes
Peter Pereira Gray
Daniel Truell (resigned as at 30 September 2017)
None of the Directors held any beneficial interest in the shares
of the Company or any interest in its parent undertaking the
Wellcome Trust through its corporate trustee, The Wellcome Trust
Limited.
Each of the Directors is an employee of the Group and receives
remuneration from the Group as an employee. No remuneration is paid
to any Director for their services as a Director.
Directors' Indemnity Policy
The Company is party to a group-wide Directors' and Officers'
liability insurance policy which includes all of the Group's
current Directors. There are no qualifying indemnity provisions (as
defined in the Companies Act 2006) that benefit the Directors of
the Company.
Statement of Directors' responsibilities
The Directors are responsible for preparing the Strategic
Report, Directors' Report and the Financial Statements in
accordance with applicable law and regulations.
Company law requires the Directors to prepare Financial
Statements for each financial year. Under that law the Directors
have prepared the Financial Statements in accordance with United
Kingdom Generally Accepted Accounting Practice (United Kingdom
Accounting Standards and applicable law), including FRS 102 the
Financial Reporting Standards applicable in U.K. and Republic of
Ireland. Under company law the Directors must not approve the
Financial Statements unless they are satisfied that they give a
true and fair view of the state of affairs of the Company and of
the profit or loss of the Company for that period. In preparing
these Financial Statements, the Directors are required to:
-- select suitable accounting policies and then apply them consistently;
-- make judgements and accounting estimates that are reasonable and prudent;
-- state whether applicable UK Accounting Standards have been
followed, subject to any material departures disclosed and
explained in the Financial Statements;
-- prepare the Financial Statements on the going concern basis
unless it is inappropriate to presume that the company will
continue in business.
The Directors are responsible for keeping adequate accounting
records that are sufficient to show and explain the Company's
transactions and disclose with reasonable accuracy at any time the
financial position of the company and enable them to ensure that
the Financial Statements comply with the Companies Act 2006. They
are also responsible for safeguarding the assets of the Company and
hence for taking reasonable steps for the prevention and detection
of fraud and other irregularities.
The Directors are responsible for the maintenance and integrity
of the company's information on its parent undertaking's (the
Wellcome Trust's) website. Legislation in the United Kingdom
governing the preparation and dissemination of Financial Statements
may differ from legislation in other jurisdictions.
The Directors consider that the Annual Report and Financial
Statements, taken as a whole, is fair, balanced and understandable
and provides the information necessary for shareholders to assess
the Company's performance, business model and strategy.
Each of the Directors, whose names are listed in the Directors'
Report confirm that, to the best of their knowledge:
-- the Financial Statements, which have been prepared in
accordance with United Kingdom Generally Accepted Accounting
Practice (United Kingdom Accounting Standards and applicable law),
including FRS 102 the Financial Reporting Standards applicable in
U.K. and Republic of Ireland, give a true and fair view of the
assets, liabilities, financial position and result of the Company;
and
-- the Directors' Report contained in this section of the Annual
Report includes a fair review of the development and performance of
the business and the position of the company, together with a
description of the principal risks and uncertainties that it
faces.
Statement of disclosure of information to auditors
Each Director in office at the date of approving this report
confirms that so far as the Director is aware, there is no relevant
audit information of which the Company's auditors are unaware and
each Director has taken all the steps that ought to have been taken
as a Director in order to make themselves aware of any relevant
audit information and to establish that the Company's auditors are
aware of that information.
Independent auditors
In accordance with Section 485 of the Companies Act 2006, a
resolution dated 11 December 2017 was passed by the members
re-appointing Deloitte LLP as auditors of the Company.
This report was approved by the Board of Directors and signed on
its behalf on 11 December 2017 by:
Peter Pereira Gray
Director
11 December 2017
INDEPENT AUDITOR'S REPORT TO THE MEMBERS OF WELLCOME TRUST
FINANCE PLC
Report on the audit of the Financial Statements
Opinion
======================================================================
In our opinion the Financial Statements:
* give a true and fair view of the state of the
company's affairs as at 30 September 2017 and of its
result for the year then ended;
* have been properly prepared in accordance with United
Kingdom Generally Accepted Accounting Practice
including Financial Reporting Standard 102 "The
Financial Reporting Standard applicable in the UK and
Republic of Ireland"; and
* have been prepared in accordance with the
requirements of the Companies Act 2006.
We have audited the Financial Statements of
Wellcome Trust Finance plc (the 'company') which
comprise:
* the statement of income and retained earnings;
* the balance sheet; and
* the related notes 1 to 16.
The financial reporting framework that has been
applied in their preparation is applicable law
and United Kingdom Accounting Standards, including
Financial Reporting Standard 102 "The Financial
Reporting Standard applicable in the UK and
Republic of Ireland" (United Kingdom Generally
Accepted Accounting Practice).
Basis for opinion
==========================================================
We conducted our audit in accordance with International
Standards on Auditing (UK) (ISAs (UK)) and applicable
law. Our responsibilities under those standards
are further described in the auditor's responsibilities
for the audit of the Financial Statements section
of our report.
We are independent of the company in accordance
with the ethical requirements that are relevant
to our audit of the Financial Statements in
the UK, including the FRC's Ethical Standard
as applied to listed public interest entities,
and we have fulfilled our other ethical responsibilities
in accordance with these requirements. We confirm
that the non-audit services prohibited by the
FRC's Ethical Standard were not provided to
the company.
We believe that the audit evidence we have obtained
is sufficient and appropriate to provide a basis
for our opinion.
Summary of our audit approach
==============================================================================
Key audit The key audit matter that we identified
matters in the current year were:
* amortisation of bond liabilities and collectability
of intercompany loans
* management override of controls
------------ ================================================================
Materiality The materiality that we used in the
current year was GBP19.3m which was
determined on the basis of 2% of
total assets.
------------ ================================================================
Scoping Audit work to respond to the risks
of material misstatement was performed
directly by the audit engagement
team.
============ ================================================================
Conclusions relating to going concern
We are required by ISAs (UK) to We have nothing
report in respect of the following to report in
matters where: respect of these
-- the directors' use of the going matters.
concern basis of accounting in
preparation of the Financial Statements
is not appropriate; or
-- the directors have not disclosed
in the Financial Statements any
identified material uncertainties
that may cast significant doubt
about the company's ability to
continue to adopt the going concern
basis of accounting for a period
of at least twelve months from
the date when the Financial Statements
are authorised for issue.
Key audit matters
==========================================================================================
Key audit matters are those matters that, in
our professional judgement, were of most significance
in our audit of the Financial Statements of
the current period and include the most significant
assessed risks of material misstatement (whether
or not due to fraud) that we identified. These
matters included those which had the greatest
effect on: the overall audit strategy, the allocation
of resources in the audit; and directing the
efforts of the engagement team.
These matters were addressed in the context
of our audit of the Financial Statements as
a whole, and in forming our opinion thereon,
and we do not provide a separate opinion on
these matters.
Amortisation of bond liabilities and collectability
of intercompany loans
========================================================================================
Key audit The company has external debt (bonds
matter description listed on the London Stock Exchange)
of GBP814m as at 30 September 2017.
This comprises two bond issues with
the following terms:
* GBP550m which is repayable on 24 July 2036 at an
interest rate of 4.625% per annum; and
* GBP275m which is repayable on 28 May 2021 at an
interest of 4.75% per annum.
The company also has receivables due
from group undertakings totalling
GBP245.5m and GBP703.8m due from its
parent.
These bonds and intercompany loans
are highly material to the company
as they account for 99.5% of total
liabilities and 98% of total assets
of the company respectively.
The bond liabilities are stated at
amortised cost using the effective
interest method and requires the calculation
of the effective interest rate for
their measurement on the balance sheet
as at 30 September 2017.
In addition, the ability of the company
to repay the external debt when it
matures and pay the interest to the
bond holders is dependent on the future
financial performance of the parent
and its group undertakings and their
ability to repay the intercompany
loans to the company.
==================== ==================================================================
How the With regards to the bond liabilities,
scope of we:
our audit * reviewed the amortisation schedule prepared by
responded management in regards to amortisation of the bonds;
to the key
audit matter
* obtained the original bond prospectuses to assess
whether the terms of the bonds agree to the inputs
used by management to calculate the effective
interest rate;
* recalculated the period to period effective interest
and the carried forward balance of the bond
liabilities until maturity;
* verified interest payments made to bond holders by
tracing back to bank statements;
* reviewed the disclosures in the Financial Statements
relating to bond liabilities as at 30 September 2017.
With regards to the collectability
of the loans given to the group undertakings
and the parent, we:
* performed a credit risk analysis by assessing the
current net asset and liquidity position of the
parent and the group undertakings;
* obtained the cash flow forecast of the parent and
group undertaking and challenged whether the
assumptions in the forecast were reasonable;
* assessed whether the cash flow forecast and the
liquidity position of the parent and group
undertakings suggested any indicators of impairment.
==================== ==================================================================
Key observations As a result of our procedures, we
concluded that the amortisation of
bond liabilities is appropriately
stated and intercompany loans are
not impaired.
==================== ==================================================================
Management override of controls
========================================================================================
Key audit In accordance with ISA 240 (UK) management
matter description override of controls is a significant
risk of material misstatement due
to fraud. Management is in a unique
position to perpetrate fraud given
their ability to manipulate accounting
records and prepare fraudulent Financial
Statements by overriding controls
that otherwise might appear to be
operating effectively.
In particular there were significant
transactions relating to intercompany
loans and transactions with associated
interests.
==================== ==================================================================
How the We assessed the design and implementation
scope of of the key controls in the financial
our audit reporting process by performing a
responded walkthrough of the financial reporting
to the key systems.
audit matter
Using computer assisted audit analytics
tools, we have analysed journals for
potential fraud characteristics and:
* traced the journals to supporting documentation and
evaluated whether the nature of the journals
indicated management override of controls;
* reviewed the journals relating to significant
accounting estimates and judgements for evidence of
bias;
* reviewed top side adjustments to assess whether the
journals posted are complete and accurate; and
* performed an analysis on any significant movements in
the intercompany balances and assessed whether the
transactions were valid.
==================== ==================================================================
Key observations As a result of our procedures, we
concluded that there was no indication
of management override of controls.
==================== ==================================================================
Our application of materiality
===============================
We define materiality as the magnitude of misstatement
in the Financial Statements that makes it probable
that the economic decisions of a reasonably knowledgeable
person would be changed or influenced. We use
materiality both in planning the scope of our
audit work and in evaluating the results of our
work.
Based on our professional judgement, we determined
materiality for the Financial Statements as a
whole as follows:
Materiality GBP19.3 million
------------------- ========================================
Basis for 2% of total assets of GBP965m
determining
materiality
------------------- ========================================
Rationale Total assets is considered as an
for the benchmark appropriate benchmark as the principal
applied activity of the entity is to issue
bonds on the London Stock Exchange
to provide financing to the Wellcome
Trust Group, and therefore it is
the key area of interest for the
users of the Financial Statements.
=================== ========================================
We agreed with the Audit Committee of the Wellcome
Trust, which oversees the group entities including
Wellcome Trust Finance plc that we would report
to the Committee all audit differences in excess
of GBP965k, as well as differences below that
threshold that, in our view, warranted reporting
on qualitative grounds. We also report to the
Audit Committee on disclosure matters that we
identified when assessing the overall presentation
of the Financial Statements.
An overview of the scope of our audit
==================================================================
Our audit was scoped by obtaining an understanding
of the entity and its environment, including
internal control, and assessing the risks of
material misstatement. Audit work to respond
to the risks of material misstatement was performed
directly by the audit engagement team.
Other information
==================================================================
The directors are responsible We have nothing
for the other information. The to report in
other information comprises the respect of these
information included in the annual matters.
report including the Strategic
Report and Director's Report,
other than the Financial Statements
and our auditor's report thereon.
Our opinion on the Financial Statements
does not cover the other information
and, except to the extent otherwise
explicitly stated in our report,
we do not express any form of
assurance conclusion thereon.
In connection with our audit of
the Financial Statements, our
responsibility is to read the
other information and, in doing
so, consider whether the other
information is materially inconsistent
with the Financial Statements
or our knowledge obtained in the
audit or otherwise appears to
be materially misstated.
If we identify such material inconsistencies
or apparent material misstatements,
we are required to determine whether
there is a material misstatement
in the Financial Statements or
a material misstatement of the
other information. If, based on
the work we have performed, we
conclude that there is a material
misstatement of this other information,
we are required to report that
fact.
Responsibilities of directors
==================================================================
As explained more fully in the directors' responsibilities
statement, the directors are responsible for
the preparation of the Financial Statements
and for being satisfied that they give a true
and fair view, and for such internal control
as the directors determine is necessary to enable
the preparation of Financial Statements that
are free from material misstatement, whether
due to fraud or error.
In preparing the Financial Statements, the directors
are responsible for assessing the company's
ability to continue as a going concern, disclosing
as applicable, matters related to going concern
and using the going concern basis of accounting
unless the directors either intend to liquidate
the company or to cease operations, or have
no realistic alternative but to do so.
Auditor's responsibilities for the audit of
the Financial Statements
==================================================================
Our objectives are to obtain reasonable assurance
about whether the Financial Statements as a
whole are free from material misstatement, whether
due to fraud or error, and to issue an auditor's
report that includes our opinion. Reasonable
assurance is a high level of assurance, but
is not a guarantee that an audit conducted in
accordance with ISAs (UK) will always detect
a material misstatement when it exists. Misstatements
can arise from fraud or error and are considered
material if, individually or in the aggregate,
they could reasonably be expected to influence
the economic decisions of users taken on the
basis of these Financial Statements.
A further description of our responsibilities
for the audit of the Financial Statements is
located on the Financial Reporting Council's
website at: www.frc.org.uk/auditorsresponsibilities.
This description forms part of our auditor's
report.
Use of our report
==================================================================
This report is made solely to the company's
members, as a body, in accordance with Chapter
3 of Part 16 of the Companies Act 2006. Our
audit work has been undertaken so that we might
state to the company's members those matters
we are required to state to them in an auditor's
report and for no other purpose. To the fullest
extent permitted by law, we do not accept or
assume responsibility to anyone other than the
company and the company's members as a body,
for our audit work, for this report, or for
the opinions we have formed.
Report on other legal and regulatory requirements
Opinions on other matters prescribed by the
Companies Act 2006
=============================================================
In our opinion, based on the work undertaken
in the course of the audit:
* the information given in the strategic report and the
directors' report for the financial year for which
the Financial Statements are prepared is consistent
with the Financial Statements; and
* the strategic report and the directors' report have
been prepared in accordance with applicable legal
requirements.
In the light of the knowledge and understanding
of the company and their environment obtained
in the course of the audit, we have not identified
any material misstatements in the strategic
report or the directors' report.
Matters on which we are required to report by
exception
=======================================================================================
Adequacy of explanations received
and accounting records We have nothing
Under the Companies Act 2006 we to report in
are required to report to you respect of these
if, in our opinion: matters.
* we have not received all the information and
explanations we require for our audit; or
* adequate accounting records have not been kept by the
company; or
* the Financial Statements are not in agreement with
the accounting records and returns.
Directors' remuneration
Under the Companies Act 2006 we We have nothing
are also required to report if to report in
in our opinion certain disclosures respect of this
of directors' remuneration have matter.
not been made.
Other matters
=====================================================
Auditor tenure
Following the recommendation of the audit committee
we were appointed by the Company at its annual
general meeting on 29 June 2016 to audit the
Financial Statements of the Company for the
period ending 30 September 2016 and subsequent
financial periods.
Our total uninterrupted period of engagement
is two years, covering periods from our appointment
through to the period ending 30 September 2017.
Consistency of the audit report with the additional
report to the audit committee
Our audit opinion is consistent with the additional
report to the audit committee we are required
to provide in accordance with ISAs (UK).
Terri Fielding, ACA (Senior statutory auditor)
For and on behalf of Deloitte LLP
Statutory Auditor
London, United Kingdom
11 December 2017
Wellcome Trust Finance plc
Statement of Income and Retained Earnings
For the year ended 30 September 2017
Year ended Year ended
30 September 30 September
Note 2017 2016
GBP GBP
-------------------------------- ----- ------------- -------------
Turnover 3 42,674,163 42,756,155
Operating income 42,674,163 42,756,155
Cost of sales 9 (39,169,739) (39,242,139)
Administrative expenses 4 (59,092) (50,603)
Operating profit 3,445,332 3,463,413
Taxation - -
Profit on ordinary activities
after taxation 3,445,332 3,463,413
Charitable donation - relating
to current year (3,445,332) (3,463,413)
Retained profit/(loss) for - -
the financial year
-------------------------------- ----- ------------- -------------
Opening shareholder's funds 137,500,000 137,500,000
Retained earnings - -
Profit for the period - -
Dividends declared and paid - -
or payable during the period
Closing shareholder's funds 137,500,000 137,500,000
-------------------------------- ----- ------------- -------------
All results are derived from continuing activities.
The Company has no other gains or losses other than the results
for the financial year as set out above, and therefore no separate
Statement of comprehensive income or Statement of changes in equity
have been presented.
The notes form part of these Financial Statements.
Wellcome Trust Finance plc
Balance Sheet
As at 30 September 2017
30 September 30 September
Note 2017 2016
GBP GBP
------------------------------------ ----- -------------- --------------
Fixed assets
Loans to Group undertakings 8 703,803,434 703,398,684
Current assets
Loans to Group undertakings 8 245,500,000 245,500,000
Amounts owed by Group undertakings 5,654,559 4,813,601
Accrued interest on loans 9,936,096 9,936,096
Prepayments 24,750 23,229
Cash at bank and in hand 7,821 7,712
261,123,226 260,280,638
Total assets 964,926,660 963,679,322
------------------------------------ ----- -------------- --------------
Creditors: amounts falling
due within one year 9 (12,745,181) (12,167,582)
------------------------------------ ----- -------------- --------------
Net current assets 248,378,045 248,113,056
------------------------------------
Total assets less current
liabilities 952,181,479 951,511,740
------------------------------------ ----- -------------- --------------
Creditors: amounts falling
due after more than one
year 9 (814,681,479) (814,011,740)
Net assets 137,500,000 137,500,000
------------------------------------ ----- -------------- --------------
Capital reserves
Called up share capital 11 137,500,000 137,500,000
Profit and loss account - -
Total shareholders' funds 10 137,500,000 137,500,000
------------------------------------ ----- -------------- --------------
The Company has no changes in equity during the year as set out
above and therefore no separate statement of changes in equity has
been presented.
The Financial Statements were approved by the Board of Directors
and authorised for issue on 11 December 2017 and signed on its
behalf by:
Peter Pereira Gray
Director
11 December 2017
Wellcome Trust Finance plc
Notes to the Financial Statements
For the year ended 30 September 2017
1. ACCOUNTING POLICIES
(a) Statement of compliance
The Company, as limited by shares, is incorporated in England
and Wales, United Kingdom under the Companies Act. The address of
the registered office is given in the Administrative Details. The
nature of the Company's operations and its principal activities are
set out in the Strategic Report.
The Company is a wholly owned subsidiary undertaking of The
Wellcome Trust through its corporate trustee, The Wellcome Trust
Limited, and is included in the Consolidated Financial Statements
of the Wellcome Trust, which are publicly available.
The Financial Statements have been prepared on a going concern
basis as well as in accordance with applicable UK accounting
standards (UK Generally Accepted Accounting Practice), including
Financial Reporting Standard 102 the Financial Reporting Standard
applicable in the United Kingdom and the Republic of Ireland ("FRS
102").
The functional and presentational currency of the Company is
considered to be pounds Sterling. The majority of transactions are
denominated in pounds Sterling.
The Company meets the definition of a qualifying entity under
FRS 102 and has therefore taken advantage of the disclosure
exemptions available to it. Exemptions have been taken in relation
to financial instruments, the presentation of a Statement of Cash
Flows and the Related Party disclosures. The equivalent disclosures
relating to the exemptions have been included in the Consolidated
Financial Statements of the Wellcome Trust.
(b) Summary of significant accounting policies
The principal accounting policies applied in the preparation of
these financial statements are set out below. These policies have
been consistently applied to all years presented, unless otherwise
stated.
Basis of preparation
The financial statements have been prepared under the historical
cost convention. The preparation of financial statements in
conformity with FRS 102 requires the use of certain significant
accounting estimates. It also requires management to exercise its
judgement in the process of applying the Company's accounting
policies. The areas involving a higher degree of judgement or
complexity, or areas where assumptions and estimates are
significant to the financial statements are disclosed in note
2.
Turnover
Turnover is interest derived from loans to Wellcome Trust
Investment Limited Partnership and Wellcome Trust Investments 1
Unlimited, undertakings in the Group, and the Wellcome Trust.
Income is calculated using the effective interest rate method and
is recognised on an accruals basis.
Cost of sales
Expenditure is the effective interest on the Bond liabilities
(as described in Bond Liabilities section below) and is recognised
on an accruals basis.
Gift Aid
Distribution of Gift Aid is equal to estimated taxable profits
of the Company at the time of the approval of the financial
statements. The Gift Aid paid within nine months of the balance
sheet date is equal to the estimated taxable profits of the Company
at time of payment. Any difference between the Gift Aid donation
accrued and the Gift Aid donation paid is recognised at the time of
payment.
Taxation
Although subject to taxation, the Company does not pay UK
Corporation Tax because its policy is to donate taxable profits as
Gift Aid to the Wellcome Trust.
Subject to the above, current tax, including UK corporation tax
and foreign tax, is provided at amounts expected to be paid (or
recovered) using the tax rates and laws that have been enacted or
substantively enacted by the balance sheet date.
Financial assets and liabilities
The Company has chosen to adopt Sections 11 and 12 of FRS 102 in
respect of financial instruments. Financial assets and financial
liabilities are recognised when the Group becomes a party to the
contractual provisions of the instrument.
Financial assets which qualify as basic financial instruments as
laid out in FRS 102 paragraph 11.8, including trade and other
receivables and cash and bank balances, are subsequently valued at
amortised cost and assessed for impairment at the end of each
reporting period.
Financial liabilities and equity instruments are classified
according to the substance of the contractual arrangements entered
into. All financial assets and liabilities are initially measured
at transaction price (including transaction costs), and
subsequently at amortised cost.
Financial assets which qualify as basic financial instruments as
laid out in FRS 102 paragraph 11.8, including trade and other
receivables and cash and bank balances, are subsequently valued at
amortised cost and assessed for impairment at the end of each
reporting period. Financial assets and liabilities are only offset
in the Balance Sheet when, and only when, a legally enforceable
right exists to set off the recognised amounts and the Group
intends either to settle on a net basis, or to realise the asset
and settle the liability simultaneously.
Financial assets are derecognised when and only when (a) the
contractual rights to the cash flows from the financial asset
expire or are settled, (b) the Company transfers to another party
substantially all of the risks and rewards of ownership of the
financial asset, or (c) the Company, despite having retained some,
but not all, significant risks and rewards of ownership, has
transferred control of the asset to another party.
Financial liabilities are derecognised only when the obligation
specified in the contract is discharged, cancelled or expires.
Loans to Group undertakings
The loans are not quoted in an active market. The loans were
recognised initially at fair value and after initial recognition
are measured at amortised cost using the effective interest
method.
Bond Liabilities
The initial measurement of the liability is equal to the
proceeds of issue less all transaction costs directly attributable
to the issue for each Bond. After initial recognition the liability
is measured at amortised cost using the effective interest method.
The Company is not required to, and therefore does not, recognise
any adjustment to fair value in the Balance Sheet and Statement of
Income and Retained Earnings.
Foreign Currencies
Transactions in currencies other than Sterling are recorded at
the rate of exchange prevailing on the dates of the transactions.
At each balance sheet date, recorded monetary assets and
liabilities and balances carried at fair value that are denominated
in foreign currencies are retranslated at the rates prevailing on
the balance sheet date. All realised and unrealised profits and
losses arising on exchange are included in net profit or loss for
the period.
2. SIGNIFICANT ACCOUNTING JUDGEMENTS AND KEY SOURCES OF
ESTIMATION UNCERTAINTY
Accounting judgements
Accounting judgements are continually evaluated and are based on
historical experience and other factors, including expectations of
future events that are believed to be reasonable under the
circumstances.
The Company has made no significant accounting judgements in the
application of the Company's accounting policies that have a
significant risk of causing a material adjustment to the carrying
amounts of assets and liabilities within the next financial
year.
Significant accounting estimates and assumptions
The Company makes estimates and assumptions to produce the
Financial Statements. The resulting accounting estimates will, by
definition, seldom equal the related actual results.
The Company has made no significant accounting estimates and
assumptions in the application of the Company's accounting policies
that have a significant risk of causing a material adjustment to
the carrying amounts of assets and liabilities within the next
financial year.
3. TURNOVER
2017 2016
GBP GBP
Interest receivable on loans
to Group undertakings 42,673,500 42,756,155
Interest receivable 663 -
on cash deposits
42,674,163 42,756,155
------------------------------ ----------- -----------
Interest receivable on loans to Group undertakings in the UK
(see note 8) is the effective interest on:
-- Loan A to Wellcome Trust Investment Limited Partnership at a fixed rate of 4.75%;
-- Loan (new bond) to Wellcome Trust at fixed rate of 4.80%; and
-- Loan C to Wellcome Trust at fixed rate of 4.00%;
-- Loan D to Wellcome Trust Investments 1 Unlimited at fixed
rate of 4.125% was novated to Wellcome Trust through its corporate
trustee, The Wellcome Trust Limited during the year.
4. ADMINISTRATIVE EXPENSES
2017 2016
GBP GBP
Auditors' remuneration 16,800 12,000
Rating
agency
fees 36,622 33,503
Tax compliance 870 270
Other 4,800 4,830
59,092 50,603
------------------------ ------- -------
Auditor's remuneration is solely in relation to the statutory
audit of the Financial Statements.
5. EMPLOYEE INFORMATION
The Company has no employees. Personnel from the Wellcome Trust
undertake the management and administration of the Company at no
incremental cost to the Wellcome Trust.
6. REMUNERATION OF DIRECTORS
The Directors of the Company received no remuneration from the
Company for their services. There were no Directors for whom
retirement benefits are accruing under a money purchase or defined
benefit scheme. The Company does not issue share options or offer
any long-term incentive schemes, so there were no Directors who
exercised share options during the year or became entitled to
shares under a long-term incentive scheme.
7. TAX ON RESULT ON ORDINARY ACTIVITIES
The profits of the Company for the year will be paid under Gift
Aid to the Wellcome Trust, a charity registered in England under
the UK Charities Act 2011 (registered charity number 210183). There
is no difference between retained profit/(loss) and taxable
profits, so there is no provision required for deferred tax.
2017 2016
GBP GBP
Profit on ordinary
activities before tax 3,445,332 3,463,413
Current tax charge
for the year:
Profit on ordinary activities
multiplied by standard rate 671,840 692,683
of corporation tax in the
UK of 19.5% (2016: 20%)
Tax relief on
gift aid donations (671,840) (692,683)
Total current - -
tax
-------------------------------- ---------- ----------
8. LOANS TO GROUP UNDERTAKINGS
Principal Interest Loan anniversary Amortised Amortised
amount rate date cost cost
per 2017 2016
annum
30 September 30 September
2006 2006
GBP % GBP GBP
Current
Assets
Loan
A 245,500,000 4.750 25 July 245,500,000 245,500,000
245,500,000 245,500,000 245,500,000
----------- ------------ --------- ----------------- ------------- -------------
Fixed
Assets
Loan (new
bond) 275,000,000 4.800 28 May 273,303,434 272,898,684
Loan
C 280,500,000 4.000 25 July 280,500,000 280,500,000
Loan
D 150,000,000 4.125 25 July 150,000,000 150,000,000
705,500,000 703,803,434 703,398,684
----------- ------------ --------- ----------------- ------------- -------------
Loans to Group undertakings are loans (the "Loans") to Wellcome
Trust Investment Limited Partnership (Loan A), Wellcome Trust (Loan
C and Loan (new bond)) and Wellcome Trust Investments 1 Unlimited
(Loan D). Loan D to Wellcome Trust Investments 1 Unlimited was
novated to Wellcome Trust through its corporate trustee, The
Wellcome Trust Limited during the year. The principal under Loan A
is repayable on demand by the Company. The principal under Loan C
and Loan (new bond) is repayable on agreement between the Company
and Wellcome Trust. The principal under Loan D is repayable on
agreement between the Company and Wellcome. The Loans have an
agreed repayment date in 19 years (Loan A, Loan C and Loan D) and 4
years (Loan (new bond)). Each Loan has a fixed redemption value
equal to the principal amount and a fixed interest rate.
9. CREDITORS
2017 2016
GBP GBP
Accruals and deferred
income 87,349 70,278
Gift Aid due to
the Wellcome Trust 3,445,332 2,884,804
Bond liabilities 9,212,500 9,212,500
Total creditors: amounts falling
due within one year 12,745,181 12,167,582
----------------------------------------- ------------ ------------
Bond liabilities 273,297,670 272,890,963
Falling due between
one and five years 273,297,670 272,890,963
--------------------------------------- ------------ ------------
Bond liabilities 541,383,809 541,120,777
Falling due after
five years 541,383,809 541,120,777
-------------------------------------- ------------ ------------
Total creditors: amounts falling
due after one year 814,681,479 814,011,740
----------------------------------------- ------------ ------------
The Bond liabilities are stated at the amortised cost using the
effective interest method for the GBP550 million 4.625% Guaranteed
Bonds due July 2036 ("GBP550 million Bonds"), issued by the Company
on 25 July 2006, and the GBP275 million 4.750% Guaranteed Bonds due
May 2021 ("GBP275 million Bonds"), issued by the Company on 28 May
2009. The Bond liabilities falling due within one year are the
unpaid coupon interest accrued for the year to 30 September 2017
for each Bond. The interest payment to the Bond holders is at a
fixed rate of 4.625% per annum (GBP550 million Bonds) and 4.750%
per annum (GBP275 million Bonds) and is paid in arrears on 25 July
or 28 May respectively each year until repayment of the Bond
principals. The bond repayments and amounts receivable from group
companies are aligned in timing for liquidity management. Effective
interest on bond liabilities is Cost of Sales in the Statement of
Income and Retained Earnings.
The obligation of the Company on the Bonds is governed by a
Trust Deed dated 25 July 2006 (GBP550 million Bonds) or 28 May 2009
(GBP275 million Bonds) between the Company, The Wellcome Trust
Limited, as trustee of the Wellcome Trust, and Citicorp Trustee
Company Limited, as the trustee for the holders of the Bonds (the
"Trust Deed" and the "new Trust Deed" respectively). The payment of
all amounts due in respect of the Bonds is unconditionally and
irrevocably guaranteed pursuant to the terms of a guarantee given
by The Wellcome Trust Limited, as corporate trustee of the Wellcome
Trust; the guarantee is part of the Trust Deed and the new Trust
Deed.
10. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS
Shareholder's
Funds
GBP
As at 30 September
2016 137,500,000
As at 30 September
2017 137,500,000
------------------------ ------------------------------
11. CALLED UP SHARE CAPITAL
2017 2016
Number GBP GBP
Authorised ordinary
shares of GBP1 each 137,500,000 137,500,000 137,500,000
------------------------- ------------ ------------------------------ ------------------------------
Issued and fully paid
ordinary shares of GBP1
each 137,500,000 137,500,000 137,500,000
-------------------------- ------------ ------------------------------ ------------------------------
12. RELATED PARTY TRANSACTIONS
The Company has taken advantage of the exemption contained in
FRS 102 Section 33 paragraph 33.1A3 "Related Party Disclosures",
which exempts it from disclosing details of transactions with the
Wellcome Trust and its subsidiary undertakings, as the Company and
its related undertakings with whom it may have transactions are
wholly owned subsidiaries of the Wellcome Trust through its
corporate trustee, The Wellcome Trust Limited. There are no other
related party transactions requiring disclosure.
13. FINANCIAL INSTRUMENTS
The Company's financial instruments comprise the loans to Group
undertakings and the liability arising from the issue of the Bonds.
The Company's loans are non-derivative financial assets with fixed
payments which are not available for sale. The Bond liability is a
non-derivative financial liability with a fixed redemption value,
fixed interest rate and fixed maturity date. The Company has not
undertaken any trading in financial instruments during the
year.
The financial instruments issued by, or held by, the Company are
Sterling denominated and at fixed interest rates and carry no
foreign exchange risk or interest rate risk.
The key risks relating to the financial instruments held by the
Company are the credit risk and liquidity risk of the
counterparties Wellcome Trust Investment Limited Partnership and
the Wellcome Trust in relation to the loans to Group undertakings.
These risks are in respect of the Wellcome Trust Investment Limited
Partnership's and the Wellcome Trust's ability to meet the interest
and principal payments as they fall due. The total value exposed to
credit risk as at 30 September 2017 is GBP964.9 million (2016:
GBP963.7 million), which comprises the value of the loans to Group
undertakings, amounts owed by Group undertakings, accrued interest
on loans and cash at bank and in hand. The liquidity risk of the
Company is mitigated by the exact matching of the cash flows from
the Company's loans to Group undertakings to those arising on the
Bond Liabilities.
Credit risk exposure of the Company's loans is reduced by the
Company only advancing loans to entities within the Group. Credit
risk exposure of the Company's remaining financial assets is
reduced by stringent selection procedures for any external
counterparties with which the Company transacts.
14. COMMITMENTS
The Company has no outstanding commitments at 30 September 2017
(2016: GBPnil).
15. ULTIMATE PARENT UNDERTAKING AND CONTROLLING PARTY
The Company is a company limited by shares. Its sole shareholder
is The Wellcome Trust Limited, in its capacity as the corporate
trustee of the Wellcome Trust, whose place of business is Gibbs
Building, 215 Euston Road, London, United Kingdom. The Company is
considered a wholly owned subsidiary of the Wellcome Trust for
accounting purposes and its assets and liabilities have been
consolidated with those of the Wellcome Trust as required by
section 9 of FRS 102.
The ultimate parent undertaking and controlling party is the
Wellcome Trust, which is the parent undertaking of the smallest and
largest group to consolidate these Financial Statements.
Copies of the Wellcome Trust Annual Report and Financial
Statements 2017 are available from the Trust's website
(www.wellcome.ac.uk) or from the company secretary.
16. EVENTS AFTER THE END OF THE REPORTING PERIOD
There have been no subsequent events requiring disclosure.
Wellcome Trust Finance plc
Administrative Details
As at 30 September 2017
Directors
Nicholas Moakes
Peter Pereira Gray
Company Secretary
Christopher Bird
Registered Company Number
5857955
Registered Office
Gibbs Building
215 Euston Road
London
NW1 2BE
Independent Auditor
Deloitte LLP
Statutory Auditor
Hill House
1 Little New Street
London
EC4A 3TR
Banker
HSBC Bank plc
31 Holborn Circus
Holborn
London
EC1N 2HR
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR UASNRBAAUAAA
(END) Dow Jones Newswires
December 12, 2017 02:00 ET (07:00 GMT)
Wellcome 4.625% (LSE:57MC)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Wellcome 4.625% (LSE:57MC)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
